New drug DA-3501 takes on tough cancers in first human trial

NCT ID NCT07481357

Recruiting now Disease control Sponsor: Dong-A ST Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing an experimental drug called DA-3501 in 51 adults with advanced stomach, gastro-esophageal junction, or pancreatic cancers that have a specific protein (CLDN18.2). Participants receive the drug by IV once every three weeks. The main goals are to find a safe dose and see if the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DA-3501 (an experimental drug given by IV every three weeks)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced stomach or pancreatic cancers that express a specific marker (CLDN18.2).
What could go wrong: This is a very early, first-in-human trial with only 51 participants. The drug may not shrink tumors or could cause serious side effects. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal cancer gastroesophageal junction adenocarcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC (STOMACH) CANCER GASTROESOPHAGEAL CANCER PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC)

Contacts and locations

Locations

CHA University Bundang Medical Center
RECRUITING

Seongnam, Bundang, 13496, South Korea
Seoul National University Bundang Hospital
RECRUITING

Seongnam, Bundang, 13620, South Korea
Severance Hospital
RECRUITING

Seoul, Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.